News AstraZeneca buys cell therapy biotech for up to $1bn AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.
News Daiichi Sankyo partners Alteogen on subcutaneous Enhertu Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu.
News 'Trust gap' is holding back AI in healthcare The potential for AI to help tackle bottlenecks in healthcare is being held back by patient scepticism and doctor concerns about bias and liability.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.